Spironolactone in the management of congestive cardiac failure: a review.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors; D001581:Benzothiadiazines; D002316:Cardiotonic Agents / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D005665:Furosemide / Q000627:therapeutic use; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008274:Magnesium / Q000097:blood; D011188:Potassium / Q000097:blood; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use; D013148:Spironolactone / Q000627:therapeutic use*
D000317:Adrenergic alpha-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D001581:Benzothiadiazines; D002316:Cardiotonic Agents; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors; D013148:Spironolactone; D005665:Furosemide; D008274:Magnesium; D011188:Potassium